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1. Introduction
A Sudden Cardiac  Death  in  Heart  Failure  Trial  (SCD-HeFT)  has  proven the  efficacy  of
prophylactic implantable cardioverter defibrillator (ICD) use for chronic heart failure pa‐
tients without sustained ventricular tachycardia (SVT) and a history of ventricular fibril‐
lation,  not  restricted in  those  with  myocardial  infarction [1].  Since  ICD is  an  expensive
device, risk stratification is required to identify heart failure patients at high risk for sud‐
den death without SVT.
Iodine-123 Metaiodobenzylguanidine (123I-MIBG) is an analogue that metabolizes in a manner
similar to that of norepinephrine (NE) [2]. 123I-MIBG is used to assess myocardial sympathetic
nervous activity, and a decrease in myocardial 123I-MIBG uptake and an increase in spillover
have been observed in patients with heart failure and are related to disease severity [3-5]. An
increase in sympathetic tone is associated with ventricular tachyarrhythmia and sudden
cardiac death [6, 7].
Therefore, the purpose of this study was to test our hypothesis that 123I-MIBG scintigraphy
may be useful in the prediction of future sudden death in heart failure patients without SVT
and a history of ventricular fibrillation.
© 2013 Yazaki et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Methods
2.1. Patients
We retrospectively examined 120 consecutive heart failure patients with a left ventricular
ejection fraction (LVEF) of less than 50 % who underwent 123I-MIBG scintigraphy between
April 1998 and December 2004. There were 84 men and 36 women with a mean age of 57±14
years ranging from 22 to 95 years. New York Heart Association (NYHA) functional class
assessment at the time of the scintigraphy showed 23 patients in class I, 66 in class II and 31 in
class III. All patients underwent cross sectional and M-mode echocardiography as well as
coronary angiography. The study population included non-ischemic dilated cardiomyopathy
in 73 patients, ischemic cardiomyopathy in 21 and others in 26 which systolic dysfunction
might be caused by valvular diseases, hypertension and/or congenital heart disease. All
patients showed stable clinical condition for at least 3 months on conventional medications
with angiotensin-converting enzyme inhibitor and diuretics. Fifty-nine patients were on β–
blocker drugs.
2.2. 123I-MIBG data acquisition
123I-MIBG is an analogue of guanethidine that is metabolized in a qualitatively similar manner
to norepinephrine at the synaptic nerve terminal. After 123I-MIBG uptakes through the uptake-1
mechanism and storages in the synaptic nerve ending, it releases according to the sympathetic
activity. Since the myocardium of patients with chronic heart failure is characterized by a
significant reduction of pre-synaptic norepinephrine uptake and post-synaptic beta-adrenor‐
eceptor density, uptake-1 function and beta–receptor downregulation can be evaluated by
123I-MIBG imaging [8]. Under resting and fasting condition, patients were injected intrave‐
nously with 111MBq of commercially available 123I-MIBG (Daiichi Radioisotopes Labs, Tokyo,
Japan). Anterior planar images were acquired 15 minutes and 3 hours after the injection and
stored in a 64 x 64 matrix by means of a scintillation camera (model ZLC 7500; Siemens, Solana,
Sweden) equipped with a long-energy, general purpose collimator interfaced to a minicom‐
puter (SCINTIPAC 7000; Shimazu, Kyoto, Japan), with a 20% window centered on the 159keV
photopeak of Iodine-123. Regions of interest (ROI) were manually drawn over the heart and
upper mediastinum by a nuclear cardiologist without knowledge of the patient’s data (Figure
1). The total number of counts of each ROI was determined, and a geometric mean was
calculated as counts per pixel. We determined the heart to mediastinum activity ratio (H/M)
for all early and delayed images. 123I-MIBG washout rate from the heart was calculated from
the difference between early and delayed images according to the formula shown in figure 1.
Demonstrable two cases are shown in figure 1. A case with NYHA class III shows lower H/M
ratio and higher washout rate as compared to a case with NYHA class I.
2.3. Follow-up information and end-point
Medical records of all patients were carefully reviewed. The primary end-point of this study
was the occurrence of cardiac death including death due to congestive heart failure and sudden
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cardiac death. Sudden cardiac death was defined as death within 1 hour after the acute onset
of symptom, death during sleep or unwitnessed death. Clinical course of the 120 patients are
summarized in figure 2. During a mean follow-up of 57±24 months, 14 patients died of
refractory heart failure and 11 died suddenly including 9 without clinical VT. Echocardia‐
graphic and hemodynamic variables ware compared among the three groups. Plasma
norepinephrin concentration of 40 patients and brain natriuretic polypeptide (BNP) of 64
patients were measured close to the time of scintigraphic examination.
H: heart; M:mediastinum; H/M: heart to mediastinum activity ratio; 123I-MIBG: Iodine-123 Metaiodobenzylguanidine;
NYHA: New York Heart Association.
Figure 1. 123I-MIBG imaging. (A) A case of NYHA functional class I status. (B) A case of NYHA functional class III status.
VT: ventricular tachycardia
Figure 2. Clinical course of all patients.
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2.4. Statistical analysis
Student’s t-test was used to compare all continuous variables expressed as mean ± SD of the
two groups. Incidence was compared by means of χ2 tests. Receiver operating characteristic
analysis was used to select the most appropriate indicator of 123I-MIBG. Survival rates were
estimated with the Kaplan-Meier method, and differences in survival assessed with the log-
rank test. Univariate and multivariate analyses of the event risks associated with selected
clinical variables used the Cox proportional hazard model (SPSS v 9.0, Chicago, IL). A p value
of < 0.05 was considered statistically significant.
3. Results
3.1. Comparisons of clinical variables among patients stratified by cause of death (table 1)
Patients who died of congestive heart failure were significantly older than those who survived,
or died suddenly without SVT. The patients with congestive heart failure death also showed
the most deteriorated echocardiographic and hemodynamic conditions among the 3 groups.
There were no statistically significant differences in any variables between surviving patients
and patients who died suddenly without SVT.
Sudden death without s-VT CHF Survived
(N=9) (N=14) (N=95)
Age (yrs.) 56.0±5.8 64.0±8.5* 55.3±14.2
Gender: Female 1 (10) 3 (21) 32(33)
β-blockers 4 (40) 5 (36) 59(63)
LVEDd (mm) 62.5±15.0 67.6±12.1† 62.8±9.8
LVEF (%) 30.8±11.2 22.6±10.3† 36.1±13.2
PCWP (mmHg) 13.1±6.3 21.0±8.7* 11.0±6.1
mPAP (mmHg) 22.8±7.4 30.9±9.0* 18.5±7.2
CI (l/min/mm2) 2.51±0.73 2.21±0.47 2.61±1.25
BNP (pg/ml) 219±255 697±516† 107±110
* p < 0.05 (for sudden death and survived patients); † p <0.05 (for survived patients)
BNP:brain natreuretic peptide; CI:cardiac index; LVDd:left ventricular end-diastolic diameter; LVEF: left
ventricular ejection fraction; PCWP:pulmonary capillary wedge pressure; mPAP:mean pulmonary wedge pressure
Table 1. Clinical Variables among the Patients Stratified by Cause of Death
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3.2. Comparisons of 123I-MIBG parameters among patients stratified by cause of death
(figure 3)
123I-MIBG parameters were better in surviving patients compared to those in patients with
death due to congestive heart failure and with sudden death. There were significant differences
in delayed H/M and washout rate of 123I-MIBG between surviving patients and patients who
died suddenly, although clinical variables were similar between the two groups.
3.3. Survival
Comparison of Kaplan-Meier survival curve was depicted in figure 4. Receiver operating
characteristic analysis indicated that the optimal cut-off point of the delayed heart to media‐
stinum ratio for all cause of cardiac death was 1.6. Survival of the patients with delayed H/M
ratio greater than 1.6 was significantly worse than that less than 1.6. Receiver operating
characteristic analysis indicated that the optimal cut-off point of heart 123I-MIBG washout rate
for all cause of cardiac death was 38%. Survival of the patients with washout rate greater than
38% was significantly worse than that less than 38%. In the analysis of washout rate, a log-rank
statistics of sudden cardiac death in heart failure patients without SVT was greater than that
of death due to heart failure, whereas similar in the analysis of the delayed H/M ratio.
3.4. Univariate predictors for heart failure death and sudden death
Univariate predictors for heart failure death are summarized in Table 2. Age, left ventricular
end-diastolic diameter, left ventricular ejection fraction (LVEF), pulmonary capillary wedge
pressure, mean pulmonary artery pressure, delayed H/M ratio, and heart 123I-MIBG washout
CHF: congestive heart failure; H/M: heart to mediastinum activity ratio; 123I-MIBG: Iodine-123 Metaiodobenzylguani‐
dine
Figure 3. Comparisons of delayed H/M (left panel) and washout rate (right panel) of 123I-MIBG among the patients
stratified by cause of death
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rate were associated with death due to heart failure. Univariate predictors for sudden cardiac
death are summarized in Table 3. Delayed H/M ratio and heart 123I-MIBG washout rate were
associated with sudden cardiac death in heart failure patients without SVT.
X2 HR 95%CI p value
Age (yrs.)* 4.39 1.07 1.004–1.141 .036
Gender :Male 0.72 0.57 0.153–2.104 .397
on β-blockade 2.25 0.40 0.119–1.327 .134
LVDd (mm)* 2.31 1.04 0.988–1.105 .129
PCWP (mmHg)* 21.3 1.24 1.131–1.357 .0000
mPAP (mmHg)* 20.8 1.19 1.105–1.283 .0000
CI (l/min/mm2)† 5.17 0.19 0.045–0.795 .023
LVEF (%)* 8.90 0.91 0.861–0.969 .003
Delayed H/M* 11.9 0.01 0.001–0.124 .0006
Washout rate (%)* 2.17 1.03 0.991–1.064 .141
Hazard ratio reflects risk with an increase of 1* and 0.1†.
CI:cardiac index; H/M:heart to mediastinum activity ratio; LVDd:left ventricular end-diastolic diameter; LVEF:
left ventricular ejection fraction; PCWP:pulmonary capillary wedge pressure; mPAP:mean pulmonary wedge pressure
Table 2. Univariate Predictors for Heart Failure Death
H/M: heart to mediastinum activity ratio; 123I-MIBG: Iodine-123 Metaiodobenzylguanidine; VT: ventricular tachycar‐
dia
Figure 4. Comparison of Kaplan-Meier survival curves. Heart failure death (left panel) abd sudden cardiac death (right
panel).
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X2 HR 95%CI p value
Age (yrs.)* 0.27 0.99 0.953–1.028 .605
Gender :Male 2.96 0.17 0.022–1.282 .085
on β-blockade 1.71 0.47 0.154–1.452 .191
LVDd (mm)* 0.41 1.02 0.965–1.073 .521
PCWP (mmHg)* 0.18 1.02 0.937–1.107 .671
mPAP (mmHg)* 0.87 1.03 0.966–1.104 .350
CI (l/min/mm2)† 0.02 0.94 0.425–2.086 .881
LVEF (%)* 1.00 0.98 0.934–1.023 .318
Delayed H/M* 12.8 0.01 0.001–0.116 .0004
Washout rate (%)* 14.8 1.06 1.027–1.086 .0001
Hazard ratio reflects risk with an increase of 1* and 0.1†.
CI:cardiac index; H/M:heart to mediastinum activity ratio; LVDd:left ventricular end-diastolic diameter; LVEF: left
ventricular ejection fraction; PCWP:pulmonary capillary wedge pressure; mPAP:mean pulmonary wedge pressure;
VT:ventricular tachycardia
Table 3. Univariate Predictors for Sudden Death without Sustained VT
3.5. Multivariate analysis
Cox multiple variable logistic regression model with a backward stepwise approach including
10 clinical variables (age, gender, on beta-blockers, left ventricular end-diastolic diameter,
pulmonary capillary wedge pressure, mean pulmonary artery pressure, cardiac index, LVEF,
delayed H/M ratio, heart 123I-MIBG washout rate) identified pulmonary capillary wedge
pressure and delayed H/M ratio as independent predictors of death due to heart failure, and
delayed H/M ratio and heart 123I-MIBG washout rate as independent predictors of sudden
cardiac death in heart failure patients without SVT (Table 4).
X2 HR 95%CI p value
PCWP* 15.3 1.28 1.078–1.409 .0000
Delayed H/M* 6.25 0.01 0.001–0.124 .012
(a) For Heart Failure Death
X2 HR 95%CI p value
Washout rate* 5.12 1.05 1.007–1.126 .024
Delayed H/M* 4.29 0.02 0.023–0.346 038
(b) For Sudden Death without Sustained VT
(a) Hazard ratio (HR) reflects risk with an increase of 1*. H/M:heart to mediastinum activity ratio; PCWP:pulmonary
capillary wedge pressure
(b) Hazard ratio (HR) reflects risk with an increase of 1*. H/M:heart to mediastinum activity ratio; VT: ventricular
tachycardia
Table 4. Multiivariate analysis
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4. Discussion
The principal finding of this study is that 123I-MIBG parameters, especially washout rate is
useful for the risk stratification of sudden cardiac death in chronic heart failure patients
without SVT. To the best of our knowledge, this is the first report to show a relation between
sudden cardiac death and cardiac sympathetic nervous function using 123I-MIBG in heart
failure patients without documented VT.
4.1. MIBG parameters and heart failure
Reduced pre-synaptic norepinephrine uptake and post-synaptic beta-adrenoreceptor density
might contribute to the remodeling process of the left ventricle in the diseased heart [9].
Increased washout and decreased uptake of 123I-MIBG in the myocardium are related to the
severity and prognosis of heart failure [10]. A recent meta-analysis including 18 studies with
a total of 1755 patients reconfirmed that decreased uptake and increased washout of 123I-MIBG
showed a poor prognosis in patients with heart failure. 123I-MIBG also has been used to assess
the functioning of the pulmonary capillary endothelium under a variety of experimental or
clinical conditions [11, 12]. Mu et al. speculated the increased lung uptake of 123I-MIBG in heart
failure patients might be due to the enhanced permeability of the pulmonary endothelial cells
[13]. We have demonstrated that the combined assessment of lung and heart 123I-MIBG uptake
may help to predict future clinical outcome in patients with idiopathic dilated cardiomyopathy
more accurately than myocardial evaluation alone [14].
4.2. Autoantibody against the beta1 adrenoreceptor and heart failure
We previously investigated the relationship between 123I-MIBG parameters and the anti-beta1-
adrenoreceptor autoantibody level in chronic heart failure patients [15]. The autoantibodies
stimulate the second extracellular domain of the beta1-adrenoreceptor like norepinephrine,
and are associated with reduced cardiac function in patients with heart failure [16]. We have
demonstrated that the anti-beta1-adrenoreceptor autoantibodies are closely associated with
cardiac sympathetic nervous activity assessed by 123I-MIBG and cardiac event in patients with
chronic heart failure [15]. Iwata et al. has reported that the autoantibodies predict VT and
sudden death in patients with idiopathic dilated cardiomyopathy [17]. These results suggest
that sudden cardiac death associated with ventricular tachyarrhythmias might be related to
sympathetic nervous activity evaluated by 123I-MIBG scintigraphy.
4.3. Cardiac sympathetic nervous function and sudden
cardiac death associated with ventricular tachyarrhythmias
Several  electrocardiographic  markers  such as  heart  rate  variability,  single-averaged elec‐
trocardiogram, and QT dispersion have been proposed for the prediction of cardiac event
in patients  with heart  failure [18-20].  Heart  rate variability is  a  noninvasive tool  for  the
condition  of  autonomic  nervous  activity  and has  been  shown to  predict  future  sudden
cardiac  death.  Tamaki  et  al.  reported  a  comparison  of  cardiac  123I-MIBG  imaging  with
other  electrocardiographic  markers,  and  concluded  that  washout  rate  of  123I-MIBG  was
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the most powerful predictor for sudden cardiac death in patients with mild-to-moderate
heart failure [21].
Using 123I-MIBG, the role of impaired cardiac sympathetic innervations has been reported in
patients with ventricular tachyarrhythmias. Akutsu et al. reported that impairment of cardiac
sympathetic nervous system predicted recurrent ventricular tachyarrhythmic events in
patients with a history of VT or fibrillation [22]. A prospective multicenter pilot study
demonstrated that only defect severity of 123I-MIBG single photon emission computed
tomography (SPECT) was predictive of inducibility of VT or fibrillation, whereas the conven‐
tional index such as H/M was not [23].
4.4. 123I-MIBG kinetics and indication for implantable cardioverter defibrillator (ICD)
A recent Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) [1] has proven the ef‐
ficacy  of  prophylactic  ICD  use  for  chronic  heart  failure  patients  without  sustained  VT
and a history of ventricular fibrillation, not restricted in those with myocardial infarction.
Since  ICD is  an  expensive  device,  risk  stratification is  required to  identify  heart  failure
patients at high risk for sudden death without sustained VT. Based on the several guide‐
lines,  prophylactic use of an ICD is recommended in patients with ventricular tachycar‐
dia  who  have  severe  systolic  dysfunction.  Nagahara  et  al.  demonstrated  that  when
combined with  plasma BNP or  cardiac  function,  impairment  of  cardiac  sympathetic  in‐
nervations would predict  an ICD shock associated with lethal  arrhythmias,  contributing
to identify  suitable  candidates  for  prophylactic  ICD implantation [24].  Severely  reduced
left  ventricular  systolic  function  is  a  powerful  predictor  of  sudden cardiac  death.  They
concluded  that  123I-MIBG  scintigraphic  evaluation  for  cardiac  sympathetic  innervations
may be an option for screening patients at  high risk for sudden cardiac death.  Further‐
more, such abnormality had incremental and additive prognostic power when combined
with left ventricular dysfunction.
Those recent reports mentioned above support our present results. Increased neuronal release
of norepinephrine and decreased efficiency in the reuptake of norepinephrine through the
uptake-1 mechanism contribute to the increased cardiac adrenergic drive, and lead to life
threatening ventricular tachyarrhythmias in patients with heart failure.
4.5. Study limitations
There are several limitations in this study. First, because of the retrospective study design,
definite conclusions could not be drawn from our present data. BNP which is one of the
important prognostic factors should be excluded in our multivariate analysis for prognostic
determinants because of imperfect data. Second, the number of cardiac death was relatively
small because the follow-up period was not long enough, so that more extensive case studies
and longer follow-ups are required to validate the results reported here.
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5. Conclusions
We investigated the relationship between 123I-MIBG findings and mode of death in patients
with chronic heart failure. Sudden cardiac death in heart failure patients is closely associated
with cardiac sympathetic nervous activity assessed by 123I-MIBG scintigraphy. Our data, thus,
confirm that increased sympathetic tone in the myocardium play a harmful role on the
progression of life-threatening ventricular tachyarrhythmias. Assessment of cardiac sympa‐
thetic nervous activity using 123I-MIBG may be helpful for the candidate selection of ICD in
heart failure patients without sustained ventricular tachycardia.
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